Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
09 mrt 2015 - 08:07
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer's disease
Bericht
First patient enrolled at leading Alzheimer Center in Amsterdam
HALLE/SAALE, Germany, 09 March 2015 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announces today that the first patient has been enrolled in the Phase 2a "SAPHIR" clinical study of its lead product PQ912 at the Alzheimer Center, VU Medical Center (VUmc), Amsterdam.
Gerelateerde downloads
Datum laatste update: 18 april 2025